Lexicon Pharmaceuticals (LXRX) Equity Average: 2009-2012
Historic Equity Average for Lexicon Pharmaceuticals (LXRX) over the last 4 years, with Sep 2012 value amounting to $248.8 million.
- Lexicon Pharmaceuticals' Equity Average rose 36.84% to $248.8 million in Q3 2012 from the same period last year, while for Sep 2012 it was $248.8 million, marking a year-over-year increase of 36.84%. This contributed to the annual value of $608.9 million for FY2011, which is 26.38% down from last year.
- Lexicon Pharmaceuticals' Equity Average amounted to $248.8 million in Q3 2012, which was down 3.15% from $256.9 million recorded in Q2 2012.
- Lexicon Pharmaceuticals' 5-year Equity Average high stood at $918.5 million for Q3 2010, and its period low was $181.8 million during Q3 2011.
- Over the past 3 years, Lexicon Pharmaceuticals' median Equity Average value was $558.3 million (recorded in 2011), while the average stood at $508.3 million.
- In the last 5 years, Lexicon Pharmaceuticals' Equity Average crashed by 80.20% in 2011 and then surged by 36.84% in 2012.
- Over the past 4 years, Lexicon Pharmaceuticals' Equity Average (Quarterly) stood at $705.7 million in 2009, then dropped by 17.38% to $583.1 million in 2010, then tumbled by 59.95% to $233.5 million in 2011, then soared by 36.84% to $248.8 million in 2012.
- Its Equity Average stands at $248.8 million for Q3 2012, versus $256.9 million for Q2 2012 and $283.3 million for Q1 2012.